Skip to main content

PONV

3
Pipeline Programs
3
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
3
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Acacia Pharma
Acacia PharmaUK - Cambridge
3 programs
3
APD421Phase 31 trial
APD421Phase 31 trial
APD421- Amisulpride for IV injectionPhase 31 trial
Active Trials
NCT02337062Completed1,147Est. Sep 2015
NCT01991821Completed368Est. Jan 2014
NCT01991860Completed364Est. Jan 2014
Qilu Pharmaceutical
Qilu PharmaceuticalChina - Jinan
1 program
AmisulpridePHASE_31 trial
Active Trials
NCT05822713Unknown516Est. Dec 2023
Eisai
EisaiChina - Liaoning
1 program
Palonosetron onlyPHASE_41 trial
Active Trials
NCT00952133Completed118Est. Apr 2011

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
EisaiPalonosetron only
Qilu PharmaceuticalAmisulpride
Acacia PharmaAPD421
Acacia PharmaAPD421- Amisulpride for IV injection
Acacia PharmaAPD421

Clinical Trials (5)

Total enrollment: 2,513 patients across 5 trials

NCT00952133EisaiPalonosetron only

Efficacy of IV Palo With IV Dexamethasone vs IV Palo for Prevention of Immediate & Delayed PONV

Start: Jul 2009Est. completion: Apr 2011118 patients
Phase 4Completed
NCT05822713Qilu PharmaceuticalAmisulpride

A Comparison of the Efficacy of Amisulpride and Placebo in the Prevention of PONV in Patients at Moderate-to-high Risk of PONV.

Start: Apr 2023Est. completion: Dec 2023516 patients
Phase 3Unknown
NCT02337062Acacia PharmaAPD421

Phase IIIb Study of APD421 in Combination as PONV Prophylaxis

Start: Feb 2015Est. completion: Sep 20151,147 patients
Phase 3Completed
NCT01991860Acacia PharmaAPD421- Amisulpride for IV injection

US Phase III Study of APD421 in PONV

Start: Aug 2013Est. completion: Jan 2014364 patients
Phase 3Completed
NCT01991821Acacia PharmaAPD421

European Phase III Study of APD421 in PONV

Start: Jul 2013Est. completion: Jan 2014368 patients
Phase 3Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 late-stage (Phase 3) programs, potential near-term approvals
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.